|
業務類別
|
Biotechnology |
|
業務概覽
|
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorizationfor an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
| 公司地址
| 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852 |
| 電話號碼
| +1 609 619-3990 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.outlooktherapeutics.com |
| 員工數量
| 17 |
| Mr. Lawrence A. Kenyon |
Director, Chief Financial Officer, Treasurer, Secretary and Principal Accounting Officer |
美元 475.00K |
26/01/2026 |
| Mr. Robert Charles Jahr |
Director, President and Chief Executive Officer |
美元 150.00K |
26/01/2026 |
|
|
| Mr. Lawrence A. Kenyon |
Director, Chief Financial Officer, Treasurer, Secretary and Principal Accounting Officer |
26/01/2026 |
| Mr. Kurt J. Hilzinger |
Independent Director |
26/01/2026 |
| Dr. Gerd U. Auffarth, M.D. |
Independent Director |
26/01/2026 |
| Mr. Ralph H. Thurman |
Lead Independent Director |
26/01/2026 |
| Mr. Robert Charles Jahr |
Director, President and Chief Executive Officer |
26/01/2026 |
| Mr. Andong Huang |
Independent Director |
26/01/2026 |
| Mr. Yezan Munther Haddadin |
Independent Director |
26/01/2026 |
| Mr. Faisal G. Sukhtian |
Chairman of the Board |
26/01/2026 |
| Dr. Julia A. Haller, M.D. |
Independent Director |
26/01/2026 |
| Mr. Julian S. Gangolli |
Independent Director |
26/01/2026 |
|
|
|
|
